Effects of domestic use of Apelis

Alpelisib (Alpelisib) is a therapy that combines two drugs. Alpelisibis a targeted drug for HER2-positive breast cancer, and fulvestrant is an aromatase inhibitor. Apelixis not currently available in China. The indications for this combination therapy currently available overseas are mainly for patients with locally advanced or metastatic breast cancer who are resistant to endocrine therapy or are no longer suitable for chemotherapyHER2-positive breast cancer.

Clinical trial results of apelvis showed that the combination therapy showed significant advantages in some key indicators compared with fulvestrant alone. It can extend patients' progression-free survival (PFS) and reduce the risk of disease progression, especially for those who have undergone multiple lines of treatment and whose cancer characteristics include HR-positive, HER2-negative and PIK3CA mutations. Apelvis is generally better tolerated than traditional chemotherapy drugs. A large phase III clinical study showed that Apelvis significantly improved the clinical benefit rate of patients, and the side effects were relatively controllable, although mild to moderate skin reactions and diarrhea may occur.

As a targeted drug, the therapeutic effect of Apelvis may vary depending on the patient's genetic variation. Therefore, genetic testing is required to determine the patient's PIK3CA mutation status before using apelvis. This helps to achieve individualized treatment and improve treatment effectiveness. Each patient's response to treatment may vary, so when using Apelvis, your doctor will decide whether to recommend this treatment based on the patient's overall condition. At the same time, doctors will closely monitor the patient's condition and side effects to ensure optimal treatment effects and quality of life.